Pyxis Capital Lease Obligations from 2010 to 2025
| PYXS Stock | USD 1.09 0.04 3.81% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 20.2 M | Current Value 11.3 M | Quarterly Volatility 8.2 M |
Check Pyxis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pyxis Oncology's main balance sheet or income statement drivers, such as Net Interest Income of 7.4 M, Interest Income of 7.4 M or Depreciation And Amortization of 3.1 M, as well as many indicators such as Price To Sales Ratio of 4.52, Dividend Yield of 0.0 or PTB Ratio of 0.79. Pyxis financial statements analysis is a perfect complement when working with Pyxis Oncology Valuation or Volatility modules.
Pyxis | Capital Lease Obligations |
Latest Pyxis Oncology's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Pyxis Oncology over the last few years. Pyxis Oncology capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Pyxis Oncology asset purchases. For example, Pyxis Oncology can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Pyxis Oncology control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Pyxis Oncology's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pyxis Oncology's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Pyxis Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 4,550,367 | |
| Geometric Mean | 130,191 | |
| Coefficient Of Variation | 180.97 | |
| Mean Deviation | 6,688,675 | |
| Median | 15,000 | |
| Standard Deviation | 8,234,733 | |
| Sample Variance | 67.8T | |
| Range | 21.3M | |
| R-Value | 0.71 | |
| Mean Square Error | 35.5T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 1,236,129 | |
| Total Sum of Squares | 1017.2T |
Pyxis Capital Lease Obligations History
About Pyxis Oncology Financial Statements
Pyxis Oncology shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Pyxis Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Pyxis Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pyxis Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 20.2 M | 11.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.